Keyphrases
National Cohort Study
100%
Bleeding Risk
100%
Rivaroxaban
100%
Patients with Cancer
100%
Recurrence Risk
100%
Cancer-associated Venous Thromboembolism
100%
Recurrent Venous Thromboembolism
37%
Major Bleeding
37%
Cancer Treatment
25%
Absolute Risk
25%
Genitourinary Cancer
25%
Attractive Alternatives
12%
Clinical Practice
12%
Breast Cancer
12%
Venous Thromboembolism
12%
Pulmonary Embolism
12%
Cancer Diagnosis
12%
Gastrointestinal Cancer
12%
All-cause Mortality
12%
Lung Cancer
12%
Initiating Treatment
12%
Selected Population
12%
Low Molecular Weight Heparin
12%
Median Time
12%
Distant Metastasis
12%
Hematological Cancer
12%
Adult Cancer
12%
Practice Setting
12%
Estimated Rates
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Bleeding
100%
Malignant Neoplasm
100%
Venous Thromboembolism
100%
Rivaroxaban
100%
Recurrent Disease
100%
Urogenital Tract Cancer
20%
All Cause Mortality
10%
Lung Embolism
10%
Lung Cancer
10%
Breast Cancer
10%
Low Molecular Weight Heparin
10%
Digestive System Cancer
10%
Distant Metastasis
10%